Abstract | BACKGROUND: METHODS: RESULTS:
Tamoxifen users were followed for a median of 2.9 years. The median duration of tamoxifen treatment increased from around 1 year among women diagnosed before 1999 to nearly 2.5 years among women diagnosed in 1999 or later. Women treated with tamoxifen had an IRR 1.06 (95 % CI 0.72-1.55) for SCC and an IRR 1.40 (95 % CI 0.95-2.08) for melanoma when compared to non-users. The observed number of these types of cancer (37 SCCs and 38 melanomas among users) did not allow stratification on calendar-period. The overall IRR for BCC was 0.96 (95 % CI 0.84-1.09), but the IRR differed by menopausal status and calendar-period at diagnosis of breast cancer. CONCLUSIONS: Our overall results indicate that tamoxifen is not associated with skin cancer. However, the inconsistency of results from stratifications prevents a firm conclusion.
|
Authors | Camilla Praestegaard, Susanne K Kjaer, Michael Andersson, Marianne Steding-Jensen, Kirsten Frederiksen, Lene Mellemkjaer |
Journal | Breast cancer (Tokyo, Japan)
(Breast Cancer)
Vol. 23
Issue 6
Pg. 908-916
(Nov 2016)
ISSN: 1880-4233 [Electronic] Japan |
PMID | 26660140
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Tamoxifen
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Hormonal
(adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy, epidemiology, pathology)
- Carcinoma, Basal Cell
(chemically induced, epidemiology, pathology)
- Carcinoma, Squamous Cell
(chemically induced, epidemiology, pathology)
- Cohort Studies
- Denmark
(epidemiology)
- Female
- Follow-Up Studies
- Humans
- Melanoma
(chemically induced, epidemiology, pathology)
- Middle Aged
- Postmenopause
- Premenopause
- Risk Factors
- Skin Neoplasms
(chemically induced, epidemiology, pathology)
- Tamoxifen
(adverse effects, therapeutic use)
- Melanoma, Cutaneous Malignant
|